FOR IMMEDIATE RELEASE
MESA, Ariz. – November 15, 2026
The Marchand Institute for Minimally Invasive Surgery is pleased to announce the publication of a systematic review and meta-analysis on prenatal cannabis exposure and newborn outcomes in BMJ Paediatrics Open, an open access journal from BMJ. The study was led by Katelyn Sainz, MD, a neonatology fellow at Dartmouth Hitchcock Medical Center, with Greg J. Marchand, MD, Director of the Marchand Institute, as corresponding author.
The paper, “Prenatal cannabis exposure and adverse neonatal outcomes: a systematic review and meta-analysis with meta-regression on tobacco co-use,” was published online as an Original Research article on November 13, 2026 (DOI 10.1136/bmjpo-2026-004876). It is open access and free to read in full.

Read the Study
Publisher page: bmjpaedsopen.bmj.com (open access, full text free)
DOI: 10.1136/bmjpo-2026-004876
PubMed: PMID 43034090
Authors: Katelyn Sainz, MD (Neonatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire); Daniela Gonzalez Herrera, McKenna Robinson, Emily Kline, Sarah Mera, Michelle Koshaba and Brooklynn O’Connell (Marchand Institute for Minimally Invasive Surgery, Mesa, Arizona); Fatma Ibrahim (Faculty of Medicine, Fayoum University, Faiyum, Egypt); and Greg J. Marchand, MD (Marchand Institute for Minimally Invasive Surgery, Mesa, Arizona).
Why Prenatal Cannabis Matters
Cannabis is the most widely used federally controlled substance in pregnancy in North America. Self-reported use has roughly tripled in two decades, from about 3% in 2002 to between 7% and 20% in some jurisdictions by 2024, and the products sold today keep getting more potent. THC crosses the placenta, and both the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine advise complete abstinence during pregnancy and breastfeeding.
The harder question is how much of the risk belongs to cannabis itself. Between half and nine in ten pregnant people who use cannabis also use tobacco, and maternal smoking is one of the strongest known causes of poor fetal growth and perinatal death. Most studies record tobacco as a single yes-or-no answer at one prenatal visit, so earlier reviews may have credited cannabis with some of tobacco’s harm. This paper set out to measure that, rather than assume it away.
It also builds on the Institute’s own 2022 meta-analysis in JAMA Network Open, which pooled 16 studies without adjusting for tobacco and has since been cited more than 200 times, including in the New England Journal of Medicine, JAMA and The BMJ.

The Largest Body of Evidence Yet
The team searched eight databases, Ovid MEDLINE, Ovid Embase, Cochrane CENTRAL, CINAHL, APA PsycINFO, Web of Science, Scopus and LILACS, from inception to September 20, 2026, with no language restriction, along with grey literature and the reference lists of earlier reviews. From more than 9,900 records, 103 reports met the inclusion criteria and 79 studies contributed data to at least one pooled outcome. Together they cover about 18.2 million pregnancies, roughly 180,000 of them exposed to cannabis, in studies published between 1982 and 2026. Thirty-nine of those studies confirmed exposure with a biological test rather than relying on self-report.
Study Design and Methodology
The review was prospectively registered with PROSPERO (CRD420251065325) and reported to PRISMA 2020 and MOOSE standards. Titles, abstracts and full texts were each screened independently by two reviewers, with a third resolving disagreements, and data were extracted independently in duplicate on a piloted form. Random-effects models pooled tobacco-unadjusted risk ratios and mean differences for nine pre-specified outcomes. The central analysis was a meta-regression on the difference in tobacco use between the cannabis-exposed and comparison groups, which is where confounding by tobacco would actually show itself. Studies that balanced tobacco between their groups to within 10 percentage points were pooled separately, and every study reporting both a tobacco-adjusted and an unadjusted estimate for the same outcome was used for a within-study comparison. Certainty of evidence was rated with GRADE by two independent reviewers.

Key Findings
- Exposure was associated with every outcome examined. Across all studies, prenatal cannabis exposure was linked to small for gestational age birth (risk ratio 1.90), low birth weight (1.72), perinatal mortality (1.76), preterm birth (1.41) and NICU admission (1.41), and to a mean birth weight 166 g lower.
- The associations tracked tobacco. For every 10-percentage-point widening of the tobacco gap between the exposed and comparison groups, the risk ratio rose by 11% to 16% for low birth weight, small for gestational age, preterm birth and NICU admission. That gap explained between a third and three fifths of the variation between studies, independent of study size.
- Fetal growth held up. In studies where tobacco use was balanced between groups, small for gestational age (1.35) and low birth weight (1.38) remained significantly raised, while preterm birth and NICU admission were no longer significant. Both growth associations also persisted in the 39 studies that verified exposure biologically.
- Perinatal mortality is the exception. Its association showed no gradient with tobacco, so tobacco does not account for it. Only three tobacco-balanced studies reported mortality, though, too few to confirm the excess directly.
- Adjustment in the source studies is unreliable. Where studies reported both versions, adjustment for a covariate set that included tobacco removed a median of about half of the association, ranging from strengthening it to erasing it entirely. Certainty of the evidence was rated very low.
Clinical Takeaways
For families and clinicians, the advice does not change: cannabis is best avoided in pregnancy. What changes is the emphasis. Because cannabis and tobacco so often travel together, counseling that addresses one without the other will miss much of the risk, and the firmest ground for that counseling is the effect on fetal growth rather than the longer list of risks usually quoted. For researchers, the authors set out three rules for future meta-analyses in this field: pool estimates that have not already been adjusted for the confounder under study, use the difference in tobacco use between groups rather than its prevalence in the exposed group, and report tobacco-balanced studies separately. They also call for individual-participant data analyses and prospective cohorts with repeated biological testing and measures of dose, timing and potency.

“Cannabis and tobacco travel together in pregnancy, and for years the research has struggled to pull them apart,” said Greg J. Marchand, MD, FACS, FACOG, FICS, corresponding author and Director of the Marchand Institute for Minimally Invasive Surgery. “When we balanced the tobacco, preterm birth and NICU admission stopped being significant. The effect on fetal growth did not.”
“Telling a pregnant patient to stop cannabis is good advice,” Dr. Marchand added. “Telling her to stop cannabis and saying nothing about the cigarettes misses much of the risk. Counsel both, and lead with fetal growth.”
Acknowledgements
The Institute congratulates lead author Katelyn Sainz, MD, of Dartmouth Hitchcock Medical Center, and thanks the Institute research team, Daniela Gonzalez Herrera, McKenna Robinson, Emily Kline, Sarah Mera, Michelle Koshaba and Brooklynn O’Connell, along with Fatma Ibrahim of Fayoum University, for the screening, extraction and assessment work behind a review of this size.
About the Marchand Institute
The Marchand Institute for Minimally Invasive Surgery is a 501(c)(3) tax-exempt non-profit research and educational institution based in Mesa, Arizona (EIN 42-2857240). The Institute produces peer-reviewed systematic reviews and meta-analyses in minimally invasive gynecologic surgery and women’s health, conducts FDA clinical trials, and trains surgeons through an SLS-accredited fellowship. All reviews are prospectively registered with PROSPERO and reported to PRISMA standards. The Institute accepts no pharmaceutical or medical device industry funding and declares no conflicts of interest. It is directed by Greg J. Marchand, MD, FACS, FACOG, FICS, a dual board-certified minimally invasive gynecologic surgeon, the first Master Surgeon in minimally invasive gynecology accredited by the Surgical Review Corporation in the United States, a member of the U.S. Department of State’s Fulbright Specialist Roster, and the holder of a Guinness World Record and two World Record Academy records for minimally invasive procedures.
For more information on our surgical fellowships or to view our library of research, please visit MarchandInstitute.org.
Media Contact
Maria A. Sainz, Director of Communications and Media Relations
Marchand Institute for Minimally Invasive Surgery
maria@marchandobgyn.com | (480) 999-0905
10238 E. Hampton Ave., Suite 212, Mesa, AZ 85209
###